CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
GBT009 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01053897
NCT01053897Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

Garnet BioTherapeutics, Inc.·interventional·Posted Jan 22, 2010·Updated Oct 24, 2013

In Brief

A Phase 2 clinical trial evaluating GBT009 and Placebo for Scar Formation. Completed, enrolled 5 participants across 2 sites.

Detailed Summary

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScar Formation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 22, 2010
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.4 years ago

Interventions

GBT009biological

Intradermal Injection following surgery

Placebobiological

Intradermal Injection following surgery